Objective: To compare cued recall measures with other memory and nonmemory tests regarding their association with a biomarker profile indicative of Alzheimer disease (AD) in CSF among patients with mild cognitive impairment (MCI).
recently proposed Research Diagnostic Criteria for the Diagnosis of AD suggested a more specific memory signature as the core clinical symptom of AD, consisting of a recall deficit which does not improve with cueing. 6, 7 Semantic cued recall tests, like the Free and Cued Selective Reminding Test (FCSRT), 8, 9 predict conversion from MCI to AD dementia within 18 -36 months. 10, 11 However, it is unclear whether cued recall tests more closely reflect AD pathology, or more accurately predict future AD dementia, than other verbal learning tests frequently employed for assessing MCI. 12 Longitudinal studies which compare the accuracy of diagnostic measures in predicting AD dementia face sample attrition, possibly insufficient follow-up times, and the problem that the categorical conversion from MCI to AD rests on clinical criteria only. We therefore compared several verbal episodic memory tests, including the FCSRT, with regard to their cross-sectional association with biomarker pathology in the CSF of subjects with broadly defined MCI. Using a validated cutoff for the A␤ 1-42 /total tau ratio, 13, 14 we tested the hypothesis that cued recall measures would be most strongly associated with a biomarker signature of prodromal AD. METHODS Subjects. Subjects were recruited between 2003 and 2007 at 14 University memory clinics collaborating within the multicenter German Dementia Competence Network (DCN). The DCN aims at defining the diagnostic and prognostic power of a range of clinical, laboratory, and imaging methods with regard to AD. The procedures for recruitment and assessment have been published previously. 15 Briefly, subjects aged 50 years or older who had approached one of the memory clinics underwent a uniform set of clinical, neuropsychological, and laboratory assessments. Subjects screened for participation were usually referred by general physicians, neurologists, or psychiatrists because of their reported cognitive problems when no obvious medical or psychiatric condition was detected. Exclusion criteria were substance abuse or dependence, major depression, insufficient German language skills, multimorbidity, comorbid condition with excess mortality, or lack of an informant.
Diagnoses of MCI and dementia were made on the basis of clinical and neuropsychological data, without reference to CSF results (see below). 15 Standard protocol approvals, registrations, and patient consent. The study was approved by the Ethics Review Board of the Erlangen medical faculty (coordinating center) and by the Ethics Committees at each individual center, and was conducted in accordance with the Declaration of Helsinki. All subjects gave written informed consent.
Neuropsychological measures and definition of MCI.
Subjects were assessed by trained neuropsychologists following standardized procedures. 15 The assessment included the Logical Memory Test of the Wechsler Memory Scale-Revised, the Consortium to Establish a Registry for Alzheimer's Disease neuropsychological battery (CERAD-NP), the Trail Making Test, and the FCSRT. The FCSRT first employs a study phase to ensure semantic encoding of all 16 items, directly followed by 3 identical recall trials, which involve a sequence of interference (counting backwards), free recall, cued recall, and selective reminding of items not recalled. 9, 16 One additional delayed free and cued recall trial 15 minutes later was also employed.
The DCN study deliberately employed a broad definition of MCI. 17 Subjects scoring more than 1 SD below age-and education-adjusted norms in either subtest of the CERAD-NP battery (verbal memory, visual memory, word fluency, naming, constructional praxis) or in the Logical Memory II (delayed recall) or in either the Trail Making Test A or B were considered MCI cases, if they had no or only minor impairments in instrumental activities of daily living (Bayer ADL score Ͻ4). 18 We here focus on episodic memory measures commonly employed for the assessment and definition of MCI. The Logical Memory II (LM) subtest from the Wechsler Memory Scale-Revised measures how many items a subject can remember from 2 stories verbally presented to her or him 30 minutes earlier. 19 The CERAD-NP contains a 10-word list which is read and immediately recalled 3 times. 20 About 15 minutes later, filled with other tasks, subjects have to recall the items presented and then to recognize them among distractors. The primary measures derived from the FCSRT are the sum of words correctly recalled with or without cues during the 3 recall trials (FCSRT total recall) and the sum of words recalled without cues (FCSRT free recall). We also explored whether the first FCSRT recall trial, which is less affected by ceiling effects than the subsequent FCSRT recall trials 2 and 3, would be particularly sensitive to an AD CSF profile. Similarly, we tested whether the delayed FCSRT free and cued recall trial would be superior to the FCSRT free and cued recall directly following the study phase. For purposes of comparison, we also examined how strongly a number of nonmemory measures would be associated with a CSF ADϩ profile. CSF measures. CSF was collected by lumbar puncture from the L3/L4 or L4/L5 intervertebral region, sampled in polypropylene test tubes with intermediate storage at site (Ϫ80°C), and then shipped on dry ice to the biobank in Erlangen without undergoing any thawing/refreezing cycles. The CSF biomarkers A␤1-42, tau, and ptau181 (Innogenetics, Ghent, Belgium) were measured by ELISA. 15 We employed the formula A␤ 42 /(240 ϩ [1.18 ϫ t-tau]) to classify the CSF profile as either indicative of AD (CSF ADϩ, n ϭ 74, AD-profile ratio Ͻ1) or not (CSF ADϪ, n ϭ 111). This formula was developed by Hulstaert et al. 13 and discriminated patients with AD from controls with high sensitivity (85%) and specificity (87%). The formula has been applied in several subsequent independent cohorts and also identified patients with potential AD-type dementia among patients with MCI with high diagnostic accuracy. 14 Statistical analysis. For the current article, we analyzed all 185 MCI cases from the DCN study with quality-controlled CSF data and complete neuropsychological data from the tests mentioned above.
The performance of CSF ADϩ and CSF ADϪ subjects was compared in a series of analyses of covariance with age, sex, and years of education as covariates. Effect sizes (Cohen d) were derived from the means and SDs for the adjusted scores. Logistic regression analyses tested whether the FCSRT total recall, as predicted, would significantly improve prediction of a biomarker pathology beyond the prediction achieved by LM and CERAD verbal delayed recall. We examined by multiple regression analyses how closely A␤ 42 and total tau, respectively, are associated with the cognitive measures. Age, sex, and years of education were entered first into all analyses, which were performed with SPSS 17. APOE4 was not entered because we wanted to compare the specific contribution of clinical neuropsychological information for predicting CSF biomarkers, irrespective of genetic information. Supplementary analyses with APOE4 as an additional predictor did not change the pattern of results (results not shown).
RESULTS MCI CSF ADϩ subjects were older, better educated, had fewer depressive symptoms, were more likely to be female, or to carry at least 1 APOE4 allele, than MCI CSFϪ subjects (table 1) .
As expected, all episodic memory measures were highly significantly related to a CSF ADϩ signature (table 2) . Among the memory measures, scores from the FCSRT discriminated best between groups (e.g., FCSRT total recall, d ϭ 0.91), while LM (d ϭ 0.74) and CERAD delayed recall (d ϭ 0.71) achieved smaller effect sizes.
Logistic regression analyses confirmed the superior ability of cued recall measures to predict the likelihood of an CSF ADϩ profile among MCI subjects (table 3) . We first ran 3 separate forward logistic regressions, with CSF ADϩ and CSF ADϪ as a criterion, with age, sex, and education as standard predictors, and with CERAD delayed recall, LM delayed recall, or FCSRT total recall as single cognitive predictors. The model 3a including the FCSRT total recall achieved a good model fit (Nagelkerkes R 2 ϭ 0.400), while the model fit was poorer for the models employing either the CERAD delayed recall (model 1a, Nagelkerkes R 2 ϭ 0.312) or the LM delayed recall (model 2a, Nagelkerkes R 2 ϭ 0.324). Importantly, adding the FCSRT total recall as a predictor to the models 1a or 2a significantly increased the model fits (table 3, models 1b and 2b). However, the reverse was not true: the model employing the FCSRT total recall could not be significantly improved by either CERAD delayed recall or LM delayed recall (models 3b and 4b).
We repeated these analyses for a restricted group of amnestic MCI (aMCI) patients, classifying subjects with either CERAD word list or LM delayed recall more than 1.5 SD below age-and educationcorrected norms as aMCI (n ϭ 125). Not surprisingly, more subjects in the CSF ADϩ group (84%) than in the CSF ADϪ group (57%) could be characterized as aMCI ( 2 [df ϭ 1] ϭ 14.8, p Ͻ 0.001). Importantly, the logistic regression analyses for aMCI yielded the same results as for the full sample, with best model fits always requiring FCSRT total recall (Nagelkerkes R 2 Ͼ ϭ 0.43).
This implies that among all memory measures employed, the FCSRT total recall reflects CSF AD pathology and best predicts the probability of presence or absence of a CSF profile indicative of AD, even in a sample selected for the presence of aMCI.
Additional regression analyses examined which neuropsychological variables best predicted either A␤ or tau levels, respectively. Both CSF markers appeared to have a unimodal distribution (figure e-1 on the Neurology ® Web site at www.neurology.org). In general, the relationship between cognitive variables was stronger with tau than with A␤ 1-42 , memory variables were more closely linked to CSF variables than nonmemory variables, and FCSRT measures were most closely linked both with tau and A␤ (table e-1 and table e -2) . This confirms that the association of FCSRT measures with CSF is independent from the specific formula chosen to define CSF ADϩ subjects, but is present across the range of variation of both A␤ 1-42 and tau in MCI. For CSF ADϩ subjects or CSF ADϪ subjects treated as separate groups, none of the regressions remained significant. DISCUSSION The main finding of this study is that cued recall measures were more closely related to a biomarker signature of AD than 2 delayed free recall measures which are frequently employed in diagnosing MCI. The FCSRT total recall (i.e., the sum of free and cued recall) outperformed not only FCSRT free recall, but also delayed free recall measures derived from verbal list learning (CERAD) or paragraph recall (LM), in predicting the likelihood of a pathologic CSF profile. This novel finding complements results from prospective clinical studies which have shown that conversions from MCI to AD dementia can be predicted by cued recall measures (FCSRT and MIS-plus, respectively) with high sensitivity and specificity. 10, 11 Our data provide new biological support for the emphasis on cued recall as a specific neuropsychological marker for early AD pathology. 6, 7 It may seem surprising that a recall measure without several minutes of delay should be most closely related to AD pathology. However, the FCSRT (but not the other memory tests of this study) employs a controlled distraction procedure (counting backwards) before each recall trial, thus ensuring that items cannot be recalled from working memory, but require episodic memory. Erasing working memory for items is probably more relevant than a mere temporal delay between encoding and recall, which is inherently variable with regard to the events during Table 3 Results of logistic regression analyses for models with different sets of predictors: Best fit requires FCSRT the interval (e.g. patients' reactions to difficult tests administered before delayed recall). All episodic memory measures discriminated well between subjects with MCI with and without an AD CSF profile and were significantly correlated with A␤ 1-42 and tau, independent of age, sex, and education. Some studies have described associations of tau with memory measures, while previous results were inconclusive with regard to A␤ 1-42 , possibly because of smaller sample sizes and different subject selection criteria. [21] [22] [23] In our sample, the association between A␤ 1-42 or tau, respectively, and episodic memory recall measures was both significant and specific, in that no associations (with the exception of the Trail Making B test) were found with nonmemory measures. This fits with other studies which found significant correlations between episodic memory performance and A␤ 1-42 burden in the brain measured with PIB-PET. 24 -26 Abnormal CSF A␤ 1-42 reaches a plateau earlier than CSF tau during the prodromal phase of AD, and memory impairment occurs even later, according to current theory. 1 This temporal sequence could explain why memory measures generally correlate more strongly with CSF tau than with CSF A␤ .
Is the FCSRT more predictive for the presence or absence of CSF AD pathology than CERAD delayed recall or LM delayed recall for psychometric reasons, e.g., because of having more trials (3 ϫ 16 items) than the CERAD (3 ϫ 10 items) or because of single item learning being more demanding than memorizing contextually linked stories (in the LM)? Such increased sensitivity possibly underlies the differential sensitivity of different free recall tasks, e.g., the CVLT-2, a 16-item word list recall test, being more sensitive to classify and predict progression of MCI than the LM. 27 However, in terms of items recalled, the FC-SRT (free plus cued recall) was less difficult than both CERAD and LM delayed recall (93%, 51%, and 23% items recalled, respectively). As the (more difficult) FC-SRT free recall was not particularly predictive, it is more likely the qualitative feature of cueing which sets the FCSRT total recall apart, possibly because patients with mediotemporal AD pathology have particular difficulties in using semantic cues.
Two neuroanatomic hypotheses could be proposed to account for the relative superiority of cued recall in predicting CSF AD pathology. First, cued recall may be most effective to isolate AD-typical hippocampal pathology from other memory retrieval deficits. 7 Indeed, cued recall procedures discriminate well between depression and MCI, 28 consistent with the view that the memory deficit in AD is an encoding deficit, rather than a retrieval deficit. The average MADRS depression score was slightly, but signifi-cantly higher in our ADϪ subjects, suggesting that somewhat depressed memory complainers with MCI, but without AD pathology, can be well detected with cued recall measures.
Cued recall might also be more sensitive for dysfunction of the parahippocampal (PHC) and entorhinal cortex (ERC). While the hippocampus is critical for binding of information to context and for recollection, the PHC, connected to the hippocampus via the ERC, supports recollection by retrieving contextually associated information. 29 Neurofibrillary tangles in the ERC occur early in the development of AD. 30 ERC volume is reduced in patients with MCI and predicts transition to AD dementia. [31] [32] [33] In support of the differential sensitivity hypothesis, the FCSRT total recall score correlates with both hippocampal and PHC/ERC volumes in patients with MCI, 34 while delayed free recall measures vary with hippocampal volume only. 35 FCSRT recall is strongly correlated with ERC volume in subjects with memory complaints. 31 Furthermore, frontal brain activation during associative retrieval correlates with left ERC volume in healthy elderly subjects, independent of hippocampal volume. 36 Thus, cued recall may capture aspects of memory subserved by ERC/PHC where AD pathology results in structural and functional loss. Further structural and functional imaging studies of cued recall in subjects with prodromal AD are needed to test this conjecture.
The 2 groups of patients did not differ with regard to verbal recognition in the CERAD, the only recognition task employed. This confirms that cueing and recognition are not interchangeable procedures and that, in line with the most recent "new lexicon" criteria 7 of prodromal AD, only a lack of normalization by cueing is sensitive to prodromal AD. However, recognition paradigms which avoid ceiling effects might be more sensitive to ADtypical memory decline than the CERAD recognition measure. 37 Reduced ceiling effects may also be the reason why the first trial of the FSCRT discriminated best between CSF ADϩ and CSF ADϪ patients. In contrast, a delayed FCSRT recall trial did not add discriminative power relative to postdistractional FCSRT recall directly after the study phase. These observations could highlight opportunities for further refinement of memory assessment in early AD detection. Brain imaging and neurochemical biomarkers of early AD now provide for an important biological validation strategy for neuropsychological methods, in addition to prospective clinical validation.
The strengths of the study include the large sample size, a quality controlled CSF measurement, an extended neuropsychological battery, and the multicenter design which resulted in increased statistical power and generalizability of the findings. The broad inclusion criteria for MCI are a strength with regard to the variance in cognitive and biological measures and their possible covariance in our cross-sectional analyses. However, it should be kept in mind that the results are derived from subjects who had been screened with the CERAD and the LM II tests for the presence of MCI. The data therefore do not allow for the conclusion that the FCSRT alone is the "best test" for all diagnostic decisions. Rather, cued recall measures like the FCSRT seem to capture unique variance of the episodic memory deficit resulting from mediotemporal AD pathology in the prodromal phase of AD. Neuropsychological characterization of suspected prodromal AD in research settings should therefore include such cued recall measures. In clinical settings, cued recall measures (more than recognition measures from frequently applied list learning tasks) likely add specificity with regard to the memory deficit indicative of prodromal AD, while free recall measures may be the most sensitive screening tools. Further research will have to determine which combination and sequence of cognitive and biomarker measures will be most sensitive and specific in identifying prodromal AD.
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